FDA Inspection 1009139 — Shandong Qilu King-phar Pharmaceutical Co., Ltd.
The FDA completed an inspection of Shandong Qilu King-phar Pharmaceutical Co., Ltd. on March 24, 2017 in Jinan. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Veterinary.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 24, 2017
- Fiscal Year
- 2017
- Product Type
- Veterinary
- Project Area
- Monitoring of Marketed Animal Drugs, Feed, and Devices
- Location
- Jinan (China)